Sight Sciences (NASDAQ:SGHT) Stock Price Down 5%

Sight Sciences, Inc. (NASDAQ:SGHTGet Rating) shares dropped 5% on Friday . The stock traded as low as $10.54 and last traded at $10.84. Approximately 7,750 shares changed hands during mid-day trading, a decline of 97% from the average daily volume of 233,435 shares. The stock had previously closed at $11.41.

SGHT has been the subject of several research analyst reports. Citigroup dropped their target price on shares of Sight Sciences from $39.00 to $35.00 and set a “buy” rating for the company in a research report on Friday, March 25th. Piper Sandler dropped their target price on shares of Sight Sciences from $23.00 to $17.00 in a research report on Wednesday, May 11th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $31.00.

The firm has a market capitalization of $483.04 million and a price-to-earnings ratio of -3.28. The company has a debt-to-equity ratio of 0.15, a quick ratio of 20.94 and a current ratio of 21.28. The company’s fifty day moving average price is $8.77 and its 200 day moving average price is $12.33.

Sight Sciences (NASDAQ:SGHTGet Rating) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.08). Sight Sciences had a negative net margin of 134.02% and a negative return on equity of 51.67%. The business had revenue of $14.88 million during the quarter, compared to analyst estimates of $13.60 million. As a group, sell-side analysts expect that Sight Sciences, Inc. will post -1.85 earnings per share for the current year.

In other Sight Sciences news, Director Staffan Encrantz acquired 300,000 shares of the company’s stock in a transaction dated Monday, May 16th. The stock was bought at an average price of $8.20 per share, for a total transaction of $2,460,000.00. Following the purchase, the director now owns 301,802 shares in the company, valued at approximately $2,474,776.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Several institutional investors have recently made changes to their positions in the stock. CNA Financial Corp increased its position in shares of Sight Sciences by 9.2% during the 4th quarter. CNA Financial Corp now owns 14,027 shares of the company’s stock worth $246,000 after purchasing an additional 1,180 shares in the last quarter. Swiss National Bank increased its position in shares of Sight Sciences by 7.3% during the 1st quarter. Swiss National Bank now owns 28,000 shares of the company’s stock worth $324,000 after purchasing an additional 1,900 shares in the last quarter. Amalgamated Bank bought a new stake in Sight Sciences during the 1st quarter worth about $31,000. California State Teachers Retirement System grew its holdings in Sight Sciences by 21.0% during the 1st quarter. California State Teachers Retirement System now owns 19,546 shares of the company’s stock worth $226,000 after acquiring an additional 3,398 shares during the last quarter. Finally, Northern Trust Corp grew its holdings in Sight Sciences by 4.7% during the 4th quarter. Northern Trust Corp now owns 104,484 shares of the company’s stock worth $1,836,000 after acquiring an additional 4,731 shares during the last quarter. Institutional investors and hedge funds own 60.76% of the company’s stock.

Sight Sciences Company Profile (NASDAQ:SGHT)

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company’s products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists.

Recommended Stories

Want More Great Investing Ideas?

Receive News & Ratings for Sight Sciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sight Sciences and related companies with MarketBeat.com’s FREE daily email newsletter.